**I. Background**

FDA is announcing the availability of a guidance for industry entitled “How to Write a Request for Designation (RFD).” This guidance addresses 21 CFR 3.7 and is intended to clarify the type of information OCP recommends that a sponsor include in an RFD. The goal of this guidance is to help a sponsor understand what information FDA needs to determine the regulatory identity or classification of a product as a drug, device, biological product, or combination product, and to assign the product to the appropriate Agency component for review and regulation.

This final guidance supersedes the previously issued RFD guidance document which was published on FDA’s Web site on August 2005. This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the Agency’s current thinking on how to write an RFD. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

**II. Paperwork Reduction Act of 1995**

This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in 21 CFR part 3 have been approved under OMB control number 0910–0523.
III. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

IV. Electronic Access

Persons with access to the Internet may obtain the document at either http://www.fda.gov/RegulatoryInformation/Guidances/ucm122047.htm or http://www.regulations.gov.

Dated: April 11, 2011.

Leslie Kux,
Acting Assistant Commissioner for Policy.

[FR Doc. 2011–9261 Filed 4–15–11; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0240]

Site Tours Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA), Center for Tobacco Products (CTP) is announcing a notice for participation in its Site Tours Program. This program is intended to provide CTP staff an opportunity to visit facilities involved in the growing, processing, or manufacturing of tobacco or tobacco products. These visits are intended to provide CTP staff with the opportunity to gain a better understanding of the tobacco industry and its operations. The purpose of this notice is to alert parties interested in participating in the Site Tours Program to submit requests to CTP.

DATES: Interested parties should submit either an electronic or written request for participation by June 17, 2011. The request should include a description of your facility, including as applicable, a list of all tobacco products processed and/or manufactured there. Please specify the physical address(es) of the site(s) for which you are submitting a request along with a proposed 1-day tour agenda.

ADDRESSES: If your facility is interested in offering a site visit, you should submit a request to participate in the program electronically to http://www.regulations.gov or in writing to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

For further information contact:
Lucinda Miner, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 877–287–1373, e-mail: lucinda.miner@fda.hhs.gov.

Supplementary Information:

I. Background

On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act (Pub. L. 111–31; 123 Stat. 1276) was signed into law, amending the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and giving FDA authority to regulate tobacco product manufacturing, distribution, and marketing. This includes, among other things, the authority to issue regulations related to health warnings, tobacco product standards, good manufacturing practices, as well as tobacco product constituents, ingredients, and additives. CTP is instituting the Site Tours Program to provide its scientific and regulatory staff the opportunity to gain a better understanding of the tobacco industry and its operations, including tobacco product manufacturing and aspects of tobacco growing, processing, and storage that may affect the physical and chemical properties of tobacco. Although FDA generally does not regulate tobacco farms and tobacco warehouses, the Agency believes that gaining a better understanding of the operations performed at these facilities may be helpful. The goals of the Site Tours Program are to: (1) Provide CTP firsthand exposure to industry’s manufacturing processes; (2) learn about control measures used by tobacco product manufacturers to ensure product consistency; (3) understand the processing of different forms of tobacco and the manufacturing processes used for various types of tobacco products and their influences on product constituents; and (4) understand how growing conditions, curing, storage, and manufacturing processes might influence the levels of tobacco or tobacco smoke constituents.

II. Description of Site Tours Program

In the Site Tours Program, small groups of CTP staff plan to observe the operations of tobacco growers, tobacco warehouses, and manufacturing facilities of cigarette, roll-your-own, and smokeless tobacco companies. Please note that the Site Tours Program is not intended to include official FDA inspections of facilities to determine compliance with the FD&C Act; rather, the program is meant to educate CTP staff and improve their understanding of the tobacco industry and its operations.

III. Site Selection

CTP plans to select one or more of each of the following types of facilities: A large cigarette manufacturing facility, a small cigarette manufacturing facility, a smokeless tobacco manufacturing facility, a burley tobacco farm, a flue-cured tobacco farm, a tobacco rolling paper facility, and a tobacco warehouse. All travel expenses associated with the site tours will be the responsibility of CTP. Final site selections will be based on the availability of CTP funds and resources for the relevant fiscal year, as well as the following factors: (1) Compliance status of the requesting facility and affiliated firm, if applicable; (2) whether the requesting facility is in arrears for user fees; (3) whether the requesting facility or affiliated firm, if applicable, has a significant request or marketing application or submission pending with FDA; and (4) whether the requesting facility will be engaged in active manufacturing or processing during the proposed time of the visit.

IV. Requests for Participation

Requests are to be identified with the docket number found in brackets in the heading of this document. Requests received by the Agency are available for public examination in the Division of Dockets Management (see ADDRESSES) between 9 a.m. and 4 p.m., Monday through Friday.

Dated: April 11, 2011.

Leslie Kux,
Acting Assistant Commissioner for Policy.

[FR Doc. 2011–9260 Filed 4–15–11; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Noncompetitive Program Extension Supplemental Awards

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

---